Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Kamada Ltd. stock logo
KMDA
Kamada
$5.20
+0.4%
$5.71
$4.08
$6.53
$298.84M1.0422,914 shs10,500 shs
MannKind Co. stock logo
MNKD
MannKind
$4.18
-0.2%
$4.33
$3.17
$5.75
$1.13B1.282.95 million shs1.78 million shs
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
$1.10
-2.2%
$1.33
$0.71
$1.96
$192.95M0.951.34 million shs2.97 million shs
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$1.87
-2.6%
$2.23
$1.86
$4.73
$21.56M1.0321,127 shs10,587 shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Kamada Ltd. stock logo
KMDA
Kamada
+1.57%+1.97%-9.60%-8.16%+15.63%
MannKind Co. stock logo
MNKD
MannKind
+0.72%+2.20%-14.49%+21.80%+7.71%
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
-1.32%+1.35%-21.88%-10.00%-0.44%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
+1.59%+1.59%-16.16%-16.52%-46.81%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Kamada Ltd. stock logo
KMDA
Kamada
4.0727 of 5 stars
3.55.00.00.01.81.73.1
MannKind Co. stock logo
MNKD
MannKind
1.6607 of 5 stars
3.50.00.00.00.00.81.9
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
1.4594 of 5 stars
3.33.00.00.00.61.70.6
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Kamada Ltd. stock logo
KMDA
Kamada
3.00
Buy$11.00111.54% Upside
MannKind Co. stock logo
MNKD
MannKind
3.00
Buy$8.0091.39% Upside
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
2.50
Moderate Buy$5.81428.41% Upside
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
2.00
HoldN/AN/A

Current Analyst Ratings

Latest TXMD, RIGL, MNKD, and KMDA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/15/2024
MannKind Co. stock logo
MNKD
MannKind
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$6.50
3/7/2024
Kamada Ltd. stock logo
KMDA
Kamada
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00
3/7/2024
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$3.00 ➝ $4.00
3/6/2024
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$2.00 ➝ $3.00
3/6/2024
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00
3/6/2024
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$1.25
2/28/2024
MannKind Co. stock logo
MNKD
MannKind
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$10.00
2/28/2024
MannKind Co. stock logo
MNKD
MannKind
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$6.50
2/22/2024
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Kamada Ltd. stock logo
KMDA
Kamada
$142.52M2.10$0.44 per share11.94$4.25 per share1.22
MannKind Co. stock logo
MNKD
MannKind
$198.96M5.69N/AN/A($0.91) per share-4.59
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
$116.88M1.65N/AN/A($0.16) per share-6.88
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$1.30M16.59N/AN/A$2.77 per share0.68

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Kamada Ltd. stock logo
KMDA
Kamada
$8.28M$0.1534.6712.68N/A5.81%5.66%3.57%5/22/2024 (Estimated)
MannKind Co. stock logo
MNKD
MannKind
-$11.94M-$0.05N/A26.13N/A-6.00%N/A-3.62%5/14/2024 (Estimated)
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
-$25.09M-$0.15N/A22.00N/A-21.47%N/A-21.21%5/7/2024 (Estimated)
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
-$10.28MN/A0.00N/AN/A-25.54%-14.87%5/20/2024 (Estimated)

Latest TXMD, RIGL, MNKD, and KMDA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/6/2024Q4 2023
Kamada Ltd. stock logo
KMDA
Kamada
$0.05$0.09+$0.04$0.09$37.71 million$36.43 million
2/27/2024Q4 2023
MannKind Co. stock logo
MNKD
MannKind
-$0.01$0.01+$0.02$0.02$52.36 million$58.47 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Kamada Ltd. stock logo
KMDA
Kamada
N/AN/AN/AN/AN/A
MannKind Co. stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
N/AN/AN/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Kamada Ltd. stock logo
KMDA
Kamada
N/A
3.43
1.64
MannKind Co. stock logo
MNKD
MannKind
N/A
3.59
3.31
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
N/A
1.86
1.76
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/A
1.72
1.72

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Kamada Ltd. stock logo
KMDA
Kamada
20.38%
MannKind Co. stock logo
MNKD
MannKind
49.55%
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
66.23%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
30.74%

Insider Ownership

CompanyInsider Ownership
Kamada Ltd. stock logo
KMDA
Kamada
36.10%
MannKind Co. stock logo
MNKD
MannKind
3.00%
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
6.43%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
1.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Kamada Ltd. stock logo
KMDA
Kamada
37857.47 million36.73 millionOptionable
MannKind Co. stock logo
MNKD
MannKind
411270.68 million262.56 millionOptionable
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
147175.41 million160.67 millionOptionable
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
111.53 million11.39 millionOptionable

TXMD, RIGL, MNKD, and KMDA Headlines

SourceHeadline
TherapeuticsMD (NASDAQ:TXMD) Now Covered by Analysts at StockNews.comTherapeuticsMD (NASDAQ:TXMD) Now Covered by Analysts at StockNews.com
americanbankingnews.com - April 25 at 2:52 AM
TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.comTherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com
americanbankingnews.com - April 19 at 2:14 AM
TherapeuticsMD gets grant for progesterone formulation for oral administration with reduced dosageTherapeuticsMD gets grant for progesterone formulation for oral administration with reduced dosage
pharmaceutical-technology.com - April 18 at 9:36 AM
TherapeuticsMD Announces Full Year 2023 Financial ResultsTherapeuticsMD Announces Full Year 2023 Financial Results
businesswire.com - March 29 at 4:00 PM
TherapeuticsMD gets grant for progesterone formulations with reduced dosage for oral administrationTherapeuticsMD gets grant for progesterone formulations with reduced dosage for oral administration
pharmaceutical-technology.com - March 28 at 11:17 AM
25 Countries With Highest Abortion Rates25 Countries With Highest Abortion Rates
msn.com - March 12 at 3:55 PM
TherapeuticsMD, Inc. (TXMD) stock historical prices & data – Yahoo FinanceTherapeuticsMD, Inc. (TXMD) stock historical prices & data – Yahoo Finance
sg.finance.yahoo.com - March 10 at 1:13 PM
TherapeuticsMD Inc TXMDTherapeuticsMD Inc TXMD
morningstar.com - December 29 at 5:48 PM
Daily Markets: Today Brings Producer Prices, Retail Sales DataDaily Markets: Today Brings Producer Prices, Retail Sales Data
nasdaq.com - November 15 at 9:54 AM
TherapeuticsMD to Consider Strategic AlternativesTherapeuticsMD to Consider Strategic Alternatives
marketwatch.com - November 14 at 7:04 PM
TherapeuticsMD exploring strategic alternatives for companyTherapeuticsMD exploring strategic alternatives for company
msn.com - November 14 at 6:27 PM
TherapeuticsMD Announces Third Quarter 2023 Financial ResultsTherapeuticsMD Announces Third Quarter 2023 Financial Results
finance.yahoo.com - November 14 at 6:27 PM
Boca Raton-based prescription service announces layoffs, says a third of workforce could be cutBoca Raton-based prescription service announces layoffs, says a third of workforce could be cut
bizjournals.com - October 4 at 5:11 PM
TherapeuticsMD Inc. stock falls Wednesday, underperforms marketTherapeuticsMD Inc. stock falls Wednesday, underperforms market
marketwatch.com - September 20 at 6:46 PM
TherapeuticsMD Inc. stock outperforms market despite losses on the dayTherapeuticsMD Inc. stock outperforms market despite losses on the day
marketwatch.com - August 15 at 7:00 PM
TherapeuticsMD Announces Second Quarter 2023 Financial ResultsTherapeuticsMD Announces Second Quarter 2023 Financial Results
finance.yahoo.com - August 14 at 7:50 AM
Micron Biomedical Appoints Brian Bernick, MD as Chairman of Its Board of DirectorsMicron Biomedical Appoints Brian Bernick, MD as Chairman of Its Board of Directors
finance.yahoo.com - August 9 at 8:38 PM
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitorsTherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors
marketwatch.com - July 5 at 6:51 PM
TherapeuticsMD Rejected by FDA, Delay Could Be FatalTherapeuticsMD Rejected by FDA, Delay Could Be Fatal
thestreet.com - July 4 at 7:28 AM
TherapeuticsMD Inc. [TXMD] Investment Appeal on the RiseTherapeuticsMD Inc. [TXMD] Investment Appeal on the Rise
knoxdaily.com - June 19 at 3:12 PM
TherapeuticsMD: From Fallen And Forgotten To Cash CowTherapeuticsMD: From Fallen And Forgotten To Cash Cow
seekingalpha.com - May 23 at 9:28 AM
TherapeuticsMD Announces First Quarter 2023 Financial ResultsTherapeuticsMD Announces First Quarter 2023 Financial Results
finance.yahoo.com - May 15 at 4:19 PM
NeuroBo Pharmaceuticals (NRBO) Appoints Mark A. Glickman to its ... - StreetInsider.comNeuroBo Pharmaceuticals (NRBO) Appoints Mark A. Glickman to its ... - StreetInsider.com
news.google.com - May 14 at 10:42 AM
NeuroBo Pharmaceuticals Appoints Mark A. Glickman to its Board of ... - citybizNeuroBo Pharmaceuticals Appoints Mark A. Glickman to its Board of ... - citybiz
news.google.com - May 13 at 7:51 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Kamada logo

Kamada

NASDAQ:KMDA
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
MannKind logo

MannKind

NASDAQ:MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Rigel Pharmaceuticals logo

Rigel Pharmaceuticals

NASDAQ:RIGL
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.
TherapeuticsMD logo

TherapeuticsMD

NASDAQ:TXMD
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.